Protagonist Therapeutics, Inc.
PTGX
$103.88
$3.933.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -304.14% | -147.29% | -73.13% | -69.38% | -65.34% |
| Total Depreciation and Amortization | -62.01% | -75.44% | -33.75% | -31.95% | -29.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.41% | 42.61% | 31.50% | 33.48% | 26.39% |
| Change in Net Operating Assets | -118.56% | 219.25% | -165.78% | -253.90% | 196.29% |
| Cash from Operations | -134.62% | -68.68% | -71.57% | -82.92% | 632.15% |
| Capital Expenditure | 24.00% | -17.34% | -65.04% | -252.53% | -97.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 134.45% | 83.99% | 70.05% | -62.98% | -844.46% |
| Cash from Investing | 133.99% | 83.53% | 69.64% | -63.82% | -829.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.80% | -11.76% | 6.92% | -33.07% | -79.95% |
| Repurchase of Common Stock | 100.00% | 20.17% | 20.17% | 20.17% | 62.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.61% | -11.56% | 7.65% | -33.24% | -80.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 264.43% | 134.87% | 82.55% | -255.52% | -173.34% |